Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

BioInvent, Audiocast with teleconference, Q3'24

By Inderes10/31/2024, 4:00 PM
BioInvent International

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Martin Welschof
00:00 - 14:11

Welcome, everyone, to our interim report. Today, I, the CEO Martin Welschof, along with Stefan, will provide an update on the current and very compelling status of our company. I will jump right into the situation. So on this slide, we summarize the activities that we had. And I will start immediately with a news, as you probably also have seen from the report this morning. So we have additional positive data for our lead compound BI-1206 targeting FCγRIIB, especially for the subcutaneous formulation. And I will get back to more details there later. And this, I think, is a very nice example of our progress. So we had good data that we presented at ASCO where we saw four responders out of four patients. And now we have additional complete responses, partial responses, and stable disease, which is actually very good. And that was actually also the reason why we immediately pushed ahead with our subcutaneous formulation in our triplet combination. But I will come back to that later. And then the events that we had. So it was a very busy third quarter. So we had additional positive efficacy data with our single agent arm of BI-1808, which is our lead compound targeting TNFR2. And that was from the Phase 2 program. And where we had a CTCL cohort, a very rare T-cell lymphoma, we saw three partial responses and one case of stable disease out of four heavily pretreated evaluable patients. And we feel this is something very interesting and exciting because it also gives us a couple of strategic options, which we might discuss later in our Q&A. Then we initiated our subcutaneous triplet combination for BI-1206, our premier program aimed at targeting FCγRIIB in conjunction with rituximab and acalabrutinib. So that has kicked off. As I mentioned earlier, we immediately started with a success. Our plan was originally to start with the intravenous formulation because at the time we decided on the triplet, the subcutaneous formulation was not ready, and we progressed quicker than planned. And that's why it is now with the Subcu formulation. We have received a notice of allowance for BI-1910, our second anti-TNF receptor two program. Um, and then also we established a new clinical trial, collaboration, and supply agreement with Merck MSD in order to evaluate BI-1607, our second anti FCγRIIB antibody in combination with KEYTRUDA as well as with ipilimumab. And I think this is also a very interesting combo. And I will come back to that later, in more detail. Then we presented two programs at ESMO. We gave a status update for BI-1910, and I will come back to that later. And then we also gave the status and could show promising anti-tumor activity in the ongoing Phase 1/2 trial with BT-001, which is our proprietary anti-CTLA-4 antibody in combination with the oncolytic virus vector from Transgene. So there, we could really show interesting anti-tumor activity in patients with solid tumors, actually quite promising, that had failed previous treatments. I will not dwell too much on this slide. It's just to remind you that we have always had a portfolio strategy. As you know, we have the first platform that has generated a number of programs. And we are currently focusing on three targets that you can see on the left-hand side of this slide. So TNFR2, where we probably have the most compelling and complete package at the moment. And TNF receptor two is actually a potential new checkpoint. So, this is very, very interesting. And I'll come back to the two different compounds that we have in a minute. So this is BI-1808 and BI-1910. Then FCγRIIB, which is another interesting target in the tumor microenvironment. And there we have two programs, BI-1206 that we're currently developing in non-Hodgkin lymphoma as well as in solid tumors. And then BI-1607, that I just mentioned, that we're now going to develop in combination with pembrolizumab and ipilimumab. And then last but not least, CTLA-4. This is our proprietary antibody that we produce in a 50-50 joint venture with Transgene, where we combine this antibody with the oncolytic virus platform from Transgene, where we also just observed compelling data. Moving then into more details on the anti-TNFR2 program. So, two compounds. And just to remind everyone. Those two compounds were selected very diligently from several hundred. And those were the two that were very interesting preclinically and could potentially cure cancer in animals. And they have two distinct modes of action. And 1808 has been deleted. And that has already shown quite interesting data that we presented at ASCO. And then also around ESMO. So in the single-agent arm, I think I have to remind everybody. So those are obviously patients that are heavily pretreated. Sometimes they have undergone even 12 rounds of treatments with the standard of care. We have seen single-agent activity, which is very rare. Normally, you would only see that in combination. And 1808 is actually very strong and has very good activity. So we saw three partial responses. One patient achieved stable disease in the CTCL patient population that I outlined. And then, of course, in addition, we had those other responders in ovarian cancer, GIST, and also in lung cancer, which I think is very compelling to basically give you a quick overview of what we're doing, because we have a broad development program around BI-1808. So what I just mentioned pertains to the single agent activity. So there we have finished the dose escalation, which is part A. And now, in Phase 2a, for ovarian cancer and melanoma, then all tumor types, which primarily include GIST and lung cancer. And then there's CTCL, which I just mentioned on the previous slide. In parallel, we run the combination with pembrolizumab because we have seen in preclinical studies that these antibodies are not only interesting as a single agent, but also seem to have synergies with pembrolizumab in combination. And there we have finished the dose escalation and are now also moving into the dose expansion cohorts. As for the single agent compound, what is new here is that we will also start the combination with pembrolizumab and paclitaxel at some point. This is especially significant for ovarian cancer, which is a very hard nut to crack, and could be very interesting for patients. And then we will have other tumor types that we have not yet announced. So I think this will be a very interesting program. And I'll come back later when we expect the further data on BI-1808. But I can mention already that we will have an update on the single agent by the end of the year. Then the second candidate that we have, 1910, had a trial in progress poster at ESMO, and there we could show a robust target occupancy. We conducted further exploration of the dose, safety, and tolerability. This trial is going very, very well. And, we will then, once we have finished the single agent dose escalation, go into several tumor types, including HCC. And the next step here actually, or the next milestone for this program, is the first Phase 1 single-agent data by the end of the year. So by the end of the year. Just to summarize it a little, we have further additional single agent data for 1808 as well as for 1910, then moving into our anti-FCγRIIB platform. Um, we have two candidates, 1206, which is our lead that we develop in a triplet for non-Hodgkin lymphoma, and then in combination with pembrolizumab for solid tumors. And then the second candidate is 1607. Starting with 1206 first. So there we had, and I mentioned it on my first slide. Very impressive clinical data. Additionally, we had one more for the subcutaneous administration. We had one additional complete response or one additional partial response, and then two more patients in stable disease, basically continuing the trend that we have seen previously. Aha. So now altogether we have two complete responses, three partial responses, and three stable diseases out of nine evaluable patients. So this is super, super compelling. And that's why we have started the triplet which is shown here on this slide with the Subcu. As I mentioned, the original plan was to use the intravenous formulation. But since we experienced rapid and robust development with the Subcu, we chose to proceed with the Subcu instead. And this is, of course, much more favorable from a product perspective because it's a difference of a couple of minutes with subcutaneous administration compared to one to two, or more, hours for IV application. So I think this also has direct product consequences. The triplet is running. I think it's a very competitive positioning because we expect to see a very strong overall response rate. What you would see also for, for instance, CAR-T as well as bispecifics, but a much, much better safety profile. So when you think about the US, for instance, the largest market for these kinds of products, the majority of cancer patients are treated at community hospitals and local hospitals, and they are overwhelmed dealing with toxicity, which is related to CAR-T or to some bispecifics. So for the majority, this would be the dream product, because then you don't have to wonder and you get the same, probably the same efficacy. You will see the first preliminary data set by the end of the year. And that, of course, will hopefully be telling. And that is of course also important for this program. So very, very excited about it. And it's running well. Then, moving on to BI-1206 in solid tumors and touching on the triplet, it's worth revisiting. So this runs in collaboration with AstraZeneca. They provide Acalabrutinib under a supply and collaboration agreement. And then, on the solid cancer side, we have the same arrangement in place with Merck, which I think is also a very interesting dynamic. The solid cancer combination also looks very interesting. So currently, we have 24 evaluable patients: we observed one complete response, one partial response, and seven patients in stable disease. These are obviously very heavily pretreated patients who do not respond anymore to this type of therapy. And the next step here will be when we disclose further Phase 1 data of this trial by mid-next year. But I will come back at the end to a summary of the milestones for next year, which are plentiful. Then, 1607, so this is actually quite interesting. 1607 is the second candidate targeting FcγRIIB. We have basically characterized this already, in combination with trastuzumab preclinically. We had two validations, one in combination with trastuzumab, the other in the triple combination with pembrolizumab and ipilimumab. And the trastuzumab combination. They presented that data from the dose escalation at the San Antonio Breast Cancer Symposium in December 2023. We were able to demonstrate that it was safe. We actually observed quite a number of cases of disease stabilization. So that was very interesting. But the main reason why we did this was to demonstrate that our compound is safe before we attempt the triple combination, which we find more compelling. This has always been considered the holy grail by many treating oncologists, as combining pembrolizumab with ipilimumab has been challenging due to the toxicity profile of ipilimumab. Essentially, what we're attempting to accomplish is enabling this combination with our antibody BI-1607. So we will soon start patient recruitment for this triplet. Phase 1B to 2A study. With the first data set actually coming in during the second half of next year. It is also a very interesting program. Then, last but not least, the anti-CTLA-4. So this is a proprietary anti-CTLA-4 antibody that we discovered first. And that has been integrated into the oncolytic platform of Transgene. And we have now presented data at ESMO in combination with pembrolizumab. We could show that we can induce tumor regression in patients who failed previous anti-PD-L1 treatment, and one patient, actually with a heavily pretreated leiomyosarcoma, was able to modulate the tumor microenvironment, turning a cold tumor into a hot tumor, which I think is very interesting. So we have early signs, essentially of efficacy, with clinical responses observed in the BT-001 in combination with KEYTRUDA, affecting two out of six patients. This study is not yet fully complete. There will be further data collection toward the end of this year. So I think now we'll hand over to Stefan for the financial part.

Stefan Ericsson
14:12 - 16:45

Thank you. I will present the financial overview for Q3 and the nine-month period from January to September. All amounts are in millions unless otherwise mentioned. Net sales were $12.8 million in Q3 2024, compared to $26.8 million in Q3 2023. That's $14 million lower in Q3 2024. That decrease is related to that. We had a $1 million milestone from Exelixis in Q3 2023. Research funding was 8 million higher in Q3 2023. However, production of antibodies for customers was 5 million higher in Q3 2024. Net sales for January to September 2024 were $23.3 million, compared to $56.1 million for the same period in 2023. The sales were $56.1 million. That's a decrease of 32.8 million. That decrease is related to the $1 million milestone that I just mentioned. Research funding was 26 million lower in 2024, but production of antibodies for customers was 4 million higher in 2024. Operating costs increased from 108 million in Q3 2023 to 120 million. In Q3 2024, that's an increase of 12 million. We had higher costs in BI-1607 and BI-1808, and somewhat higher costs in BI-1910. We had lower costs in BI-1206 and somewhat higher personnel costs in Q3 2024. For January to September, the increase of operating costs was 53 million, from 315,000,000 in 2023 to 368,000,000 in 2024. We had significantly higher costs in BI-1808, BI-1607, and BI-1910. We had somewhat lower costs for BT-001, and personnel costs in 2024 were quite higher compared to 2023. The loss for Q3 2024 was -97.2 million, and we had a loss for January to September 2024 of -312.5 million. Liquid funds, current and long-term investments. End of September amounted to a total of 979 million. Over to you, Martin.

Martin Welschof
16:46 - 19:43

Thank you. Thank you, Stefan. So then I will close the presentation with this slide. As I mentioned already during my presentation, I will summarize the event, not the events, the milestone, the remaining milestones for this year, and then also provide an outlook for next year. So, as already mentioned. So we are still expecting updates this year for our two entities, Eph receptor two antibody and antibodies BI-1808 as well as BI-1910. And as you can see, we call this our TNF receptor superfamily. This is a very compelling data set compared to what is out there from the competition. And, for BI-1808, we'll have additional single-agent Phase 2 data by the end of the year. And then, for BI-1910, the first single-agent Phase 1 data. Uh, then also for our second lead program, which is BI-1206 targeting FcγRIIB, we'll have the first patient preliminary patient data by the end of the year. This is the combination that I mentioned with rituximab. And then next year will also obviously be very busy, as the last few months have been quite active for BioInvent. So we are now moving actually into what quite an interesting phase. Quite interesting phase. Next year will be even busier. You can imagine, based on this rich portfolio that we have, that it should drive quite significant value. During the first half, we'll have further single agent data for BI-1808 and additional data for the triplet. BI-1206 in combination with rituximab and acalabrutinib. And then, as I mentioned, also for. BI-1206. And that will also include the subcutaneous data and solid tumors in combination with pembrolizumab. Pembrolizumab. So that will be during the first half. And typically, we would target. ASCO as well as. Aha. So that's at least what we have in mind. Um, and then for the second half. There will be BI-1808 and pembrolizumab combo data. The Phase 2 data for the BI-1910 solid tumor. Single agent data. And then potentially also the first BI-1910 solid tumor pembrolizumab combo data. So. I think that will be quite interesting. And there, we try, of course, to target conferences such as ASCO. And then, also in the second half of next year, the BI-1607 combination will enable combined therapy with pembrolizumab and ipilimumab. BI-1607. That will also be during the second half of next year. So I think I will end our presentation here and then open up for Q&A.

Operator
19:49 - 20:17

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Richard Romanus from Redeye. Please go ahead.

Unknown 1
20:20 - 20:42

Good evening. Thanks for the presentation. I have a few questions. Um, starting with the AstraZeneca bit. Do you have any comments on interest from AstraZeneca? And it seems this trial is progressing quicker than the other one involving BI-1206. Are they involved, or is it just you pushing this program?

Martin Welschof
20:44 - 22:05

Um, so obviously there is interest from AstraZeneca, maybe to start with that one first. I think, um, I don't know whether we are the only ones, but we are one of the very rare supply and cooperation collaboration agreements that they have. Um, and basically when we approached them with this idea because we had some data and then mainly also other ideas, they liked it very much. So there's definitely interest, and I think it's worthwhile to mention. So, we are targeting in the triplet study that we are running; follicular lymphoma will also include other non-Hodgkin lymphomas. Other non-Hodgkin lymphomas. But AstraZeneca is quite interested in follicular lymphoma because they have only approval for mantle cell lymphoma. So I think that is quite interesting. And of course, at the end, it will be data-driven. But I would say if we see a good response and good safety, that's what we expect. There will definitely be interest from AstraZeneca. And I wouldn't say that this is running much quicker. Um, I think also our other studies are important because you have to see that the BI-808 is actually quite a broad program. And I think it has also expanded quite quickly. I would say that. And there's no specific push for one or the other. We all try to do all of them as quickly as we can. Yeah.

Unknown 1
22:08 - 22:26

Okay. And, how about the new BI-1206 SC data? To me, they appear a bit better than the IV data they represented. Do you agree? And do you think that might be due to better receptor occupancy?

Martin Welschof
22:27 - 23:24

Yes. So we're currently characterizing it. So absolutely, I agree. So, it seems to have more activity. And of course, the subcutaneous administration I can also mention has an improved safety profile. You know, IV administration was also safe. But you remember. So, there's quite a bit of background noise. Remember that we had some infusion-related reactions, which clinically didn't do any harm, essentially comparable to what you would see with rituximab. But with the subcutaneous administration, this issue is completely resolved. That was also one of the reasons why we developed. The second reason was that we wanted to have something more user-friendly. And then, this was kind of surprising; we didn't necessarily expect that. It looks like this is more active, and we are analyzing it. Absolutely. But we can't tell yet exactly where this is coming from. It's just an observation for the time being, and we are analyzing it.

Unknown 1
23:26 - 23:42

Yes. Yeah, sure. Next up, I wanted to ask about trastuzumab. Are you planning any combination trials? Um, with the. I was referring to BI-1607.

Unknown 2
23:43 - 23:43

Yeah.

Martin Welschof
23:43 - 24:31

So with BI-1607, as I tried to explain during my presentation. Preclinically, we validated both the combination with trastuzumab and the triplet regimen. We think from both a patient perspective and a commercial perspective. The triplet combination is probably most interesting. That's why we are favoring it. And the reason why we started with trastuzumab is really to see what the antibody does. And also to establish safety, because in the triple combination it will be more complicated. So now we know BI-1607 is completely safe because we didn't have any toxicity issues, which of course is very important once we go on the triplet combination. So for the time being, we are focusing on the triplet combination.

Unknown 1
24:34 - 25:00

Yeah. Okay. I read some interesting news about your strategic and other licensed programs, for example, the HMI 115. Do you have any comments on those programs, since they seem to be, in this case, phase three ready and the endometriosis results look really interesting?

Martin Welschof
25:00 - 25:45

Absolutely. You're right. So I think all this, you know, we have roughly 5 or 6 programs with companies such as Takeda, Mitsubishi, and Daiichi, etc. And now we have two programs that are phase three ready, which is one program from Takeda and the other one from Bayer Hope. This is something that is in the public domain, but they have not started yet. Um, regarding the others, they are probably moving forward. Um, I'm not looking at the slide at the moment, so I just have to try to remember this: we're probably moving soon from phase one to phase two, but at least there are two programs which are essentially phase three ready. And this is, of course, super interesting. Absolutely.

Unknown 1
25:48 - 26:14

Um, final question about your cash position. Quite soon, you used to have a really good runway, and soon you'll be approaching a one-year runway. Um, are you planning on reducing that in any way, or how would you? What are your ideas on maintaining a strong cash position?

Martin Welschof
26:15 - 27:04

Well, there are various possibilities, but. So, we currently have a runway until the end of Q1 2026, which I think is very good. Most biotech companies don't have that these days. And obviously now we're moving into a phase where it's not only interesting for investors, but also for corporates. Um, and that will also be an ambition of the management team, which is, of course, completely data dependent. But I think if we develop the data as we're doing at the moment, on the same trajectory, then we should have a good chance to also do collaborations with corporates that could generate significant cash. Absolutely.

Unknown 1
27:06 - 27:14

How important do you think the CTCL data will be with BI-1808 in the short term for a potential deal?

Martin Welschof
27:15 - 28:47

Yeah. Cutaneous T-cell lymphoma (CTCL) is interesting for various reasons. So first of all, this is a smaller indication. So we're currently looking into that in order to explore strategic clinical development possibilities, because then you could probably run a pivotal phase two trial, a smaller one at some time point. And we're currently working on that. And we'll of course provide those updates to the market once we have them. What we can say is that the current treatment shows a response rate. But this is still the early days. Right. It's just some patients, but hopefully by the end of this year or early next year, we'll see more patients. This currently looks to have a stronger response rate than what is currently the standard of care, which is super interesting. At the same time, this point is also safe because the standard of care that is currently out there is not safe. It's extremely toxic. So I think this could be something very interesting. But again, what we see at the moment is still early, yet it could indeed provide a potential strategic partnering opportunity. In the case where we continue to observe the data we are currently seeing, this could be classified as an orphan indication. And if you get orphan designation, there's potentially a fast track. Etcetera. Etcetera. So, I think this is very, very interesting. Absolutely.

Unknown 1
28:49 - 28:52

Okay. Great. Thanks. That's all for me today.

Martin Welschof
28:53 - 28:54

Thank you, Richard.

Operator
28:57 - 29:02

The next question comes from Dan Xiaoyi of Pareto Securities. Please go ahead.

Unknown 3
29:05 - 29:23

Thank you for taking my questions. One aspect to clarify is the type of patients you're enrolling for BI-1910 in HCC. Do you find patients there that are not treated with checkpoint inhibitors?

Martin Welschof
29:24 - 29:58

Yes. During the dose escalation phase, we naturally focus on that particular patient. But this is applicable more for the dose expansion cohort. So currently, it's all comers that we are enrolling. And of course, we try to focus on this specific patient population for specific reasons, which I don't want to discuss here. You know, the competitive landscape. And that's also why we haven't disclosed yet what we will do besides HCC. So currently it's all-comers within focus on that patient population.

Unknown 3
29:59 - 30:06

Okay. Thank you. And can you share with us if there are some patients in that group who are checkpoint-naïve?

Martin Welschof
30:06 - 30:09

There will be an update by the end of the year then.

Unknown 3
30:10 - 30:15

Okay. That's right. Thank you. But I can tell you.

Martin Welschof
30:15 - 30:22

To give a bit of flavor in just two minutes. So the update that we'll have by the end of the year will not only be about safety.

Unknown 3
30:24 - 31:04

Okay. Thank you. And how do you see the difference in subcutaneous effect? At least now we know it in NHL. We don't yet know about solid tumors, but it's considered similarly effective in follicular lymphoma patients. What are you concluding? From my perspective, it is kind of additional confirmation when we see the same drugs combined. But we see stronger effects with the subcutaneous version, which makes logical sense. But do you see that as well, or do you think that is not something we could conclude from this? Yes.

Martin Welschof
31:04 - 31:48

So what I can tell is that the subcutaneous version is also behaving very nicely in solid cancer. And we will soon switch to subcutaneous. There, only so we see the same. What shall I say. Better, stronger, or. Yeah. Call it just better activity in solid tumors as well as in non-Hodgkin lymphoma. So it's not only there. So the non-Hodgkin lymphoma is just a little bit further advanced because that's where we started. We then enrolled it into solid cancer as well, and the development in solid cancer looks very promising. And you could see there was one slide when we moved into dose expansion. So there will be only subcu.

Unknown 3
31:50 - 31:58

Okay. Thank you. And maybe a follow-up on that. Can you share a bit on the patient distribution of BI-1206 subcutaneous solid tumors?

Unknown 2
31:59 - 32:00

Uh.

Martin Welschof
32:00 - 32:32

Not yet. So basically, it's the same as what you have already seen. So, you know, melanoma, melanoma, sarcoma. So it's a mix of patients. So there's not a big difference compared to the IV. And then, when we move forward into dose expansion, which will of course only involve the Subcu, I think the focus was on lung cancer. And those are, of course, also patients that we currently have in the dose escalation.

Unknown 3
32:35 - 32:37

Okay. Thank you very much.

Martin Welschof
32:37 - 32:38

Thank you, Dan.

Operator
32:41 - 32:47

The next question comes from Sebastian van der Scott from Van Lanschot Kempen. Please go ahead.

Unknown 3
32:49 - 33:17

Hi guys. Congrats on the progress. Just a few questions from my side. On BI-1206, I think you just mentioned that you would like to see good efficacy for the triplet combination. You currently have around 50% for the combination with rituximab for both subcutaneous and intravenous administrations. Is there any data available for rituximab plus BTK inhibitors in non-Hodgkin lymphoma? Just to get a sense of what would be a good benchmark.

Unknown 2
33:17 - 33:18

Yeah.

Martin Welschof
33:18 - 33:27

Basically, I don't have all the benchmarks in mind, but what we are expecting is an overall response rate of around 80%.

Unknown 3
33:29 - 33:50

Around 80%. Okay. And then on BI-1808, could you maybe provide some insight on what type of data we are going to get by year-end 2024? How many new patients can we expect for each of the different indication cohorts, and what metrics will you provide the data?

Unknown 2
33:50 - 33:50

Yes.

Martin Welschof
33:50 - 34:30

So basically, there will be further safety and efficacy data. We basically expect to maintain the good safety profile that we have. So we don't expect anything else at the moment, at least. And now, of course, there will be further data, specifically additional CTCL data. We have continued to recruit more patients and have included additional cohorts. No forecasts are being provided for these as it's difficult to make predictions. Of course, we have recruitment rates. Etcetera. Et cetera. But it's always difficult to predict. But it will be those from those expansion cohorts that you have seen on this one slide where we presented the trial design.

Unknown 3
34:33 - 34:38

Okay. So then I can assume like a handful of patients for each cohort. Yes.

Unknown 4
34:40 - 34:40

Okay.

Unknown 3
34:41 - 34:53

And then, what's interesting, you just mentioned the partnered assets that are phase three ready. Could you provide some insights into the economic terms of those partnered assets?

Unknown 2
34:53 - 34:53

Yeah.

Martin Welschof
34:53 - 35:24

So, we have never disclosed this. So you will learn when we release it to the market, because the agreement we have, for instance with Mitsubishi and others, is that we don't disclose the milestones or the economics, but those are standard deals. There was an upfront payment, we had preclinical and clinical development milestones, and later there will be commercial milestones and royalties. And what we do is, as soon as a milestone is triggered, we issue a press release to the market.

Unknown 3
35:28 - 35:31

We expect milestones with the start of the Phase 3 study.

Unknown 2
35:33 - 35:33

Yes.

Martin Welschof
35:33 - 35:50

So you will learn when we disclose. But you know, this is of course a very important step for the clinical development program of a product. So, of course, for us, it's a super strong validation because.

Unknown 2
35:50 - 35:50

You know.

Martin Welschof
35:50 - 36:16

That you put something into phase one, maybe into phase two, but then it's a big step to go into phase three. So this is of course a very important milestone not only for Takeda and Bayer but also for BioInvent, because it shows that our antibodies have the capabilities that you can move them all the way through and hopefully turn them into successful products.

Unknown 3
36:18 - 36:21

Okay. Got it. Thank you so much and have a great day.

Martin Welschof
36:21 - 36:23

Thank you, Sebastian.

Operator
36:30 - 36:38

There are no more questions at this time. So I hand the conference back to the speakers for any written questions or closing comments.

Martin Welschof
36:40 - 37:47

Yes, thank you very much. So that will be the closing comments, because we are already quite over time. So, I will end with the milestones for next year once again. As I mentioned, it has been a very busy couple of months. So I think we have shown that we moved our portfolio successfully not only into Phase 1, but also into Phase 2, at least for the two lead programs, BI-1808 and BI-1206. And that, of course, sets the company up for a very interesting 2025, because then we will have further Phase 2 data for BI-1808 as well as BI-1206, and then also BI-1910. It will come along nicely. So, I think also there, we're quite excited since we have probably the most compelling and complete TNFR2 platform compared to our competitors. So, um, yeah, as a closing remark here. Next year will be extremely exciting and will position the company for strong value generation. Thank you very much.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…